Drug
Darapladib clinical trials
Also written SB-480848.
- studies test it
- 21
- open now
- 0
- in phase 3
- 3
- first study started
- 2003
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
21 studies that test it; most in 2008 (5)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 5 |
| 2009 | 1 |
| 2010 | 2 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 5
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses darapladib is read from its arms, and is right about nine times in ten.
Testing it · 21
- Integrated Biomarker And Imaging Study - 2CompletedPhase 2GlaxoSmithKlineNCT00268996Written as SB-480848
- A Phase II Clinical Study of SB-480848 in Dyslipidemic PatientsCompletedPhase 2GlaxoSmithKlineNCT00734032Written as SB480848 40mg EC Tablet
- The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 TrialCompletedPhase 3GlaxoSmithKlineNCT01000727Written as Darapladib 160 mg
- The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy TrialCompletedPhase 3GlaxoSmithKlineNCT00799903Written as Darapladib
- To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy VolunteersCompletedPhase 1GlaxoSmithKlineNCT01751074Written as Darapladib 160 mg
- A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal ImpairmentCompletedPhase 1GlaxoSmithKlineNCT01711723Written as Darapladib 160 mg
- Study to Evaluate Darapladib in Moderately Hepatically Impaired SubjectsCompletedPhase 1GlaxoSmithKlineNCT01154114Written as darapladib
- Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).CompletedPhase 1GlaxoSmithKlineNCT01852565Written as Darapladib
- Darapladib China PKCompletedPhase 1GlaxoSmithKlineNCT02000804Written as darapladib 160mg
- Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT01873339Written as Darapladib
- Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedPhase 1GlaxoSmithKlineNCT02058641Written as Darapladib
- Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in HumansCompletedPhase 3Mayo ClinicNCT01067339Written as darapladib
- Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid EndarterectomyCompletedPhase 2GlaxoSmithKlineNCT01916720Written as SB-480848 40 mg
- A Study To Determine The Effect Of SB-480848 On AsthmaCompletedPhase 1GlaxoSmithKlineNCT00368576Written as SB 480848, tablets
- A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese MenCompletedPhase 1GlaxoSmithKlineNCT00551317Written as Darapladib (SB480848)
- A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular EdemaCompletedPhase 2GlaxoSmithKlineNCT01506895Written as darapladib
- A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848CompletedPhase 1GlaxoSmithKlineNCT00743860Written as darapladib
- A Study With Darapladib to Collect Tolerability InformationCompletedPhase 1GlaxoSmithKlineNCT00704431Written as SB-480848 (darapladib)
- Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-CompletedPhase 1GlaxoSmithKlineNCT00622830Written as SB-480848 (Darapladib)
- Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The HeartCompletedPhase 1GlaxoSmithKlineNCT00411073Written as Darapladib
Codes
What other systems call darapladib · ClinicalTrials.gg INT005278
- MeSH (NLM) C529040darapladibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) UI1U1MYH09DARAPLADIBConfirmed FDA, NLM, Wikidata
- Wikidata Q5222103darapladibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72985DarapladibOne source FDA
- DrugBank DB06311One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C529040 | darapladib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | UI1U1MYH09 | DARAPLADIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5222103 | darapladib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72985 | Darapladib | One source FDA |
| DrugBank | DB06311 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.